Actinium Pharmaceuticals, Inc. (ATNM)
Largest Insider Buys in Sector
ATNM Stock Price History Chart
ATNM Stock Performance
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Insider Activity of Actinium Pharmaceuticals, Inc.
Over the last 12 months, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Actinium Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $4,372 was made by SETH SANDESH (Chairman & CEO) on 2018‑12‑10.
List of Insider Buy and Sell Transactions, Actinium Pharmaceuticals, Inc.
| 2018-12-10 | Chairman & CEO | 10,000 0.0095% | $0.44 | $4,372 | -37.79% | |||
| 2018-12-10 | Principal Financial Officer | 10,000 0.0095% | $0.43 | $4,350 | -37.79% | |||
| 2018-11-19 | Chief Scientific Officer | 10,000 0.01% | $0.45 | $4,499 | -31.69% | |||
| 2018-07-17 | CEO | 10,000 0.0094% | $0.79 | $7,900 | -28.76% | |||
| 2018-06-15 | Principal Financial Officer | 12,000 0.0109% | $0.50 | $6,000 | +14.10% | |||
| 2018-04-19 | Chairman & CEO | 5,000 0.0045% | $0.38 | $1,900 | +50.00% | |||
| 2018-02-28 | director | 22,730 0.0257% | $0.43 | $9,774 | +25.81% | |||
| 2017-08-02 | Chairman & CEO | 33,333 0.0538% | $0.75 | $25,000 | -3.28% | |||
| 2017-08-02 | Executive Vice President | 10,000 0.0161% | $0.75 | $7,500 | -3.28% | |||
| 2017-06-15 | Chairman and CEO | 7,500 0.013% | $1.16 | $8,725 | -45.52% | |||
| 2017-06-15 | Chief Medical Officer | 5,000 0.0083% | $1.11 | $5,550 | -45.52% | |||
| 2017-06-15 | Principal Financial Officer | 3,500 0.0061% | $1.17 | $4,095 | -45.52% | |||
| 2016-12-30 | Executive Chairman | 5,000 0.0104% | $0.88 | $4,400 | +16.57% | |||
| 2016-12-12 | Executive Chairman | 5,000 0.0104% | $0.98 | $4,900 | +5.15% | |||
| 2016-08-31 | Sale | 10 percent owner | 136,853 0.2928% | $1.83 | $251,118 | -34.31% | ||
| 2016-08-30 | Sale | 10 percent owner | 56,074 0.1174% | $1.81 | $101,254 | -33.90% | ||
| 2016-08-29 | Sale | 10 percent owner | 25,000 0.0529% | $1.72 | $42,875 | -28.88% | ||
| 2016-08-26 | Sale | 10 percent owner | 25,000 0.052% | $1.70 | $42,620 | -29.07% | ||
| 2016-08-16 | Sale | 10 percent owner | 5,029 0.0107% | $1.72 | $8,652 | -26.18% | ||
| 2016-08-15 | Sale | 10 percent owner | 4,439 0.0093% | $1.72 | $7,635 | -25.87% |
Insider Historical Profitability
| Memorial Sloan-Kettering Cancer Center | 10 percent owner | 4709561 15.0967% | $1.22 | 0 | 25 | |
| SETH SANDESH | Chairman & CEO | 153333 0.4915% | $1.22 | 10 | 0 | <0.0001% |
| DAVE KAUSHIK J | CEO and Interim CFO | 88500 0.2837% | $1.22 | 1 | 0 | <0.0001% |
| O'Loughlin Steve | Principal Financial Officer | 35500 0.1138% | $1.22 | 3 | 0 | <0.0001% |
| Shetty Ajit | director | 22730 0.0729% | $1.22 | 1 | 0 | +25.81% |
| Nicholson, C. David | director | 15000 0.0481% | $1.22 | 1 | 0 | <0.0001% |
| Ray Nitya G. | Executive Vice President | 10000 0.0321% | $1.22 | 1 | 0 | <0.0001% |
| Ludwig Dale L. | Chief Scientific Officer | 10000 0.0321% | $1.22 | 1 | 0 | <0.0001% |
| Berger Mark Stanley | Chief Medical Officer | 5000 0.016% | $1.22 | 1 | 0 | <0.0001% |
| TRAVERSA SERGIO | director | 3000 0.0096% | $1.22 | 2 | 0 | <0.0001% |
| Steinhart Richard I | director | 2500 0.008% | $1.22 | 1 | 0 | <0.0001% |
| MAZANET ROSEMARY | director | 100 0.0003% | $1.22 | 1 | 0 |
Institutional Investor Ownership
| BlackRock | $13.38M | 5.74 | 1.71M | +1.01% | +$133,689.42 | <0.0001 | |
| The Vanguard Group | $11.32M | 4.86 | 1.45M | +6.02% | +$642,944.76 | <0.0001 | |
| Geode Capital Management | $4.67M | 2 | 595,720 | +4.59% | +$204,942.45 | <0.0001 | |
| State Street | $4.31M | 1.85 | 550,845 | +8.68% | +$344,543.46 | <0.0001 | |
| Northern Trust | $1.81M | 0.77 | 230,605 | +1.86% | +$32,987.79 | <0.0001 | |
| Verition Fund Management Llc | $1.54M | 0.66 | 196,437 | New | +$1.54M | 0.02 | |
| Marshall Wace | $1.19M | 0.51 | 152,469 | New | +$1.19M | <0.01 | |
| Brandywine Global Investment Management | $1.14M | 0.49 | 145,600 | 0% | +$0 | 0.01 | |
| Dimensional Fund Advisors | $1.13M | 0.49 | 144,465 | -2.02% | -$23,270.76 | <0.0001 | |
| Citadel Advisors LLC | $846,540.00 | 0.36 | 108,115 | +233.61% | +$592,785.49 | <0.0001 | |
| Nuveen | $777,879.00 | 0.33 | 99,346 | 0% | +$0 | <0.0001 | |
| Susquehanna International Group | $762,110.00 | 0.33 | 97,332 | +59.57% | +$284,511.04 | <0.01 | |
| Hudson Bay Capital Management LP | $729,787.00 | 0.31 | 93,204 | New | +$729,787.00 | 0.01 | |
| Bridgeway Capital Management | $657,454.00 | 0.28 | 83,966 | 0% | +$0 | 0.01 | |
| Virtu Financial Llc | $642,000.00 | 0.28 | 82,029 | +319.16% | +$488,835.39 | 0.06 | |
| Charles Schwab | $596,709.00 | 0.26 | 76,208 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $553,236.00 | 0.24 | 70,656 | -29.02% | -$226,216.33 | <0.0001 | |
| BNY Mellon | $527,477.00 | 0.23 | 67,366 | -41.32% | -$371,487.38 | <0.0001 | |
| Millennium Management LLC | $527,828.00 | 0.23 | 67,411 | New | +$527,828.00 | <0.0001 | |
| ROYCE & ASSOCIATES INC | $391,500.00 | 0.17 | 50,000 | 0% | +$0 | <0.01 | |
| Jane Street Capital | $390,999.00 | 0.17 | 49,936 | +68.01% | +$158,275.67 | <0.0001 | |
| Bank of America | $305,855.00 | 0.13 | 39,062 | -21.14% | -$81,995.64 | <0.0001 | |
| RhumbLine Advisers | $251,576.00 | 0.11 | 32,131 | +1.53% | +$3,781.74 | <0.0001 | |
| UBS | $217,016.00 | 0.09 | 27,716 | -6.86% | -$15,981.01 | <0.0001 | |
| Lighthouse Investment Partners, LLC | $206,775.00 | 0.09 | 26,408 | New | +$206,775.00 | 0.01 | |
| Creative Financial Designs Inc Adv | $178,798.00 | 0.08 | 22,835 | +15.33% | +$23,764.04 | 0.02 | |
| Group One Trading | $176,637.00 | 0.08 | 22,559 | +347.6% | +$137,173.79 | <0.01 | |
| Barclays | $152,000.00 | 0.07 | 19,369 | -48.65% | -$143,979.76 | <0.0001 | |
| American Century Investments | $147,611.00 | 0.06 | 18,852 | New | +$147,611.00 | <0.0001 | |
| Intrepid Financial Planning Group Llc | $125,280.00 | 0.05 | 16,000 | 0% | +$0 | 0.05 | |
| National Asset Management Inc | $86,136.00 | 0.05 | 14,550 | 0% | +$0 | <0.01 | |
| Deutsche Bank | $106,143.00 | 0.05 | 13,556 | -4.39% | -$4,870.24 | <0.0001 | |
| Wells Fargo | $107,013.00 | 0.05 | 13,667 | +9.84% | +$9,583.95 | <0.0001 | |
| American International Group | $106,942.00 | 0.05 | 13,658 | +0.68% | +$720.36 | <0.0001 | |
| MetLife Investment Management | $108,383.00 | 0.05 | 13,842 | 0% | +$0 | <0.01 | |
| AM Investment Strategies | $99,000.00 | 0.04 | 12,582 | New | +$99,000.00 | 0.03 | |
| New York State Common Retirement Fund | $99,000.00 | 0.04 | 12,583 | -0.4% | -$393.39 | <0.0001 | |
| JPMorgan Chase | $92,269.00 | 0.04 | 11,784 | -36.55% | -$53,150.20 | <0.0001 | |
| Perritt Capital Management Inc | $93,960.00 | 0.04 | 12,000 | 0% | +$0 | 0.01 | |
| Invesco | $90,248.00 | 0.04 | 11,526 | -0.3% | -$274.05 | <0.0001 | |
| Goldman Sachs | $87,281.00 | 0.04 | 11,147 | -27.99% | -$33,927.39 | <0.0001 | |
| SMH CAPITAL INC. | $78,300.00 | 0.03 | 10,000 | New | +$78,300.00 | 0.02 | |
| Advisor Group Holdings Inc | $80,938.00 | 0.03 | 10,150 | +52.63% | +$27,909.65 | <0.0001 | |
| Voya Investment Management LLC | $79,631.00 | 0.03 | 10,170 | -7.66% | -$6,608.51 | <0.0001 | |
| Simplex Trading Llc | $71,000.00 | 0.03 | 9,071 | -46.92% | -$62,758.02 | <0.01 | |
| Royal Bank of Canada | $43,000.00 | 0.02 | 5,488 | -59.45% | -$63,042.64 | <0.0001 | |
| Citigroup | $36,417.00 | 0.02 | 4,651 | +18.47% | +$5,676.70 | <0.0001 | |
| Qube Research & Technologies | $25,001.00 | 0.01 | 3,193 | New | +$25,001.00 | <0.0001 | |
| Legal & General | $23,631.00 | 0.01 | 3,018 | 0% | +$0 | <0.0001 | |
| Fidelity Investments | $22,720.00 | 0.01 | 2,902 | -0.89% | -$203.56 | <0.0001 |